StockNews.AI
FLGT
StockNews.AI
172 days

Fulgent Reports Fourth Quarter and Full Year 2024 Financial Results

1. Fulgent Genetics reported $76.2 million revenue, a 14% growth year-over-year. 2. Company faced a GAAP loss of $5.9 million for Q4 2024.

Earnings
-1.53%Current Return
VS
+1.56%S&P 500
$15.6902/28 07:19 AM EDTEvent Start
$15.4503/03 07:31 AM EDTLatest Updated
2m saved
Insight
Article

FAQ

Why Neutral?

While revenue growth is positive, the GAAP loss could raise concerns among investors, similar to past instances where high growth was tempered by losses, affecting investor sentiment.

How important is it?

The article provides key earnings figures critical for investors assessing FLGT's financial health, impacting stock performance outlook.

Why Short Term?

The financial results will have immediate effects on investor perception, influencing short-term stock price behavior, as seen in similar earnings reports.

Related Companies

N/A
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Results: Total Revenue of $76.2 million Core Revenue1 grew 14% year-over-year to $76.0 million GAAP loss of $5.9 million, or ($0.19) per share Non-GAAP income.

Related News